0 GSK Nuvalent buyout: Proven success with second FDA approval November 18, 2026 Dr. Roza Riyan GSK Nuvalent buyout delivers second FDA approval, marking a significant milestone in pharma innovation.
0 USFDA Form 483 Observations: The Real Impact on Gufic Biosciences October 24, 2026 Dr. Roza Riyan USFDA Form 483 observations raise concerns for Gufic Biosciences’ Pithampur plant operations. Discover what this means for the company.